GHRP-2

Research Only

Growth Hormone Secretagogues · GHRP

GHRP-2 is one of the most potent growth hormone releasing peptides, stimulating GH release through the ghrelin receptor.

What is GHRP-2?

GHRP-2 is one of the most potent growth hormone releasing peptides, stimulating GH release through the ghrelin receptor. It produces a stronger GH release than ipamorelin but with more side effects including increased hunger, cortisol, and prolactin elevation.

Also known as: Growth Hormone Releasing Peptide-2, Pralmorelin

How Does GHRP-2 Work?

Binds to GHS-R1a (ghrelin receptor) in the pituitary and hypothalamus, triggering growth hormone release. Also stimulates appetite through ghrelin pathway activation. Unlike ipamorelin, it is less selective and affects cortisol and prolactin levels.

What is GHRP-2 Used For?

Growth hormone stimulation
Muscle growth
Fat loss
Appetite stimulation

Potential Side Effects

Increased appetite
Water retention
Cortisol elevation
Prolactin increase
Numbness/tingling

Contraindications

Active cancer
Pregnancy
Diabetes (affects blood sugar)

FDA Legal Status

United States — FDA

Research Only

This peptide is currently investigational and not approved for clinical use.

Related Peptides

Ipamorelin

Compoundable (Rx)

Growth Hormone Secretagogues

Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to produce growth hormone with...

CJC-1295

Compoundable (Rx)

Growth Hormone Secretagogues

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone relea...

GHRP-6

Research Only

Growth Hormone Secretagogues

GHRP-6 is one of the original growth hormone releasing peptides. It strongly stimulates both GH release and appetite (hu...

Frequently Asked Questions

What is the difference between GHRP-2 and ipamorelin?

Both stimulate GH release via the ghrelin receptor, but ipamorelin is more selective. GHRP-2 produces a stronger GH pulse but also increases cortisol, prolactin, and appetite. Ipamorelin is preferred for its cleaner side effect profile despite slightly lower GH output.

Quick Facts

Legal Status (USA): Research Only
Evidence Rating: BModerate Evidence (Some Human Data)
Class / Subclass: Growth Hormone Secretagogues / GHRP
Administration: subcutaneous
Typical Dosage: 100-300mcg 2-3x daily
Half-Life: ~1-2 hours
Year Discovered: 1997

Sources

PubMed 9849822

Last updated: 2026-04-01

Sources & references

Primary sources used for the dosing, mechanism, side-effect, and regulatory claims on this page. Verify time-sensitive information (regulatory status, prescribing details) on the source before relying on it for medical decisions. See our disclaimer.

PubMed PMID 9849822 — peer-reviewed primary literature on GHRP-2.
FDA Federal Register — official notice record for FDA regulatory actions and Category 1 / 503A bulk-substance updates.